Yohannes Tesfaigzi to Cell Line, Tumor
This is a "connection" page, showing publications Yohannes Tesfaigzi has written about Cell Line, Tumor.
Connection Strength
0.183
-
Chand HS, Montano G, Huang X, Randell SH, Mebratu Y, Petersen H, Tesfaigzi Y. A genetic variant of p53 restricts the mucous secretory phenotype by regulating SPDEF and Bcl-2 expression. Nat Commun. 2014 Nov 27; 5:5567.
Score: 0.078
-
Bredow S, Juri DE, Cardon K, Tesfaigzi Y. Identification of a novel Bcl-2 promoter region that counteracts in a p53-dependent manner the inhibitory P2 region. Gene. 2007 Dec 01; 404(1-2):110-6.
Score: 0.047
-
Tomchaney M, Contoli M, Mayo J, Baraldo S, Li S, Cabel CR, Bull DA, Lick S, Malo J, Knoper S, Kim SS, Tram J, Rojas-Quintero J, Kraft M, Ledford JG, Tesfaigzi Y, Martinez FD, Thorne CA, Kheradmand F, Campos SK, Papi A, Polverino F. Paradoxical effects of cigarette smoke and COPD on SARS-CoV-2 infection and disease. BMC Pulm Med. 2021 Aug 23; 21(1):275.
Score: 0.031
-
Belinsky SA, Grimes MJ, Picchi MA, Mitchell HD, Stidley CA, Tesfaigzi Y, Channell MM, Liu Y, Casero RA, Baylin SB, Reed MD, Tellez CS, March TH. Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res. 2011 Jan 15; 71(2):454-62.
Score: 0.015
-
Wang X, Chen W, Zeng W, Bai L, Tesfaigzi Y, Belinsky SA, Lin Y. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther. 2008 May; 7(5):1156-63.
Score: 0.012